Smooth Muscle Myosin Inhibition: A Novel Therapeutic Approach for Pulmonary Hypertension
Figure 6
The effect of CK-165 and sildenafil in rats with monocrotaline-induced pulmonary hypertension.
CK-165 decreased RSVP following intratracheal nebulization of 30 mg/kg in rats with monocrotaline induced pulmonary artery hypertension by 18.0±3.8% (p<0.05) when compared with vehicle treated group. The decrease is similar to that in monocrotaline rats treated with 100 mg/kg/day sildenafil (20.3±4.5%) for 7 days and treatment with CK-165 does not appear to have additive effects when co-administered with sildenafil.